(Q34610632)

English

Parkinson's psychosis

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Parkinson's psychosis (English)

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

1 reference

based on heuristic

inferred from title

Parkinson's disease

1 reference

based on heuristic

inferred from title

Hubert H Fernandez

2

object named as

Hubert H Fernandez

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

author name string

Laura B Zahodne

1

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

publication date

1 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

Current treatment options in neurology

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

200-211

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

https://scigraph.springernature.com/pub.10.1007/s11940-010-0072-y

0 references

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Pathophysiology and treatment of psychosis in Parkinson's disease: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Treatment of psychosis in Parkinson's disease: safety considerations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Clozapine in Parkinson's disease psychosis: 5-year follow-up review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Donepezil in the treatment of hallucinations and delusions in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Risperidone in levodopa-induced psychosis in advanced Parkinson's disease: an open-label, long-term study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Cholinesterase inhibition in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Risperidone for hallucinations in levodopa-treated Parkinson's disease patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Exacerbation of parkinsonism by tacrine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Levodopa-induced psychosis: a kindling phenomenon

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

7 July 2018

Risk factors for nursing home placement in advanced Parkinson's disease.

1 reference

https://api.crossref.org/works/10.1007%2FS11940-010-0072-Y

21 January 2018

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS11940-010-0072-Y

21 January 2018

Acute delirium after withdrawal of amantadine in Parkinson's disease

1 reference

https://api.crossref.org/works/10.1007%2FS11940-010-0072-Y

21 January 2018

Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Cognitive changes in Parkinson's disease patients with visual hallucinations.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Hallucinations in Parkinson disease in the prelevodopa era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Aripiprazole in psychosis associated with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Ziprasidone in the treatment of Parkinson's disease psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Delusions and hallucinations in dementia with Lewy bodies: worsening with memantine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Antipsychotic dose-sparing effect with addition of memantine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Best clinical practice with ziprasidone: update after one year of experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Parenteral ziprasidone: a new atypical neuroleptic for emergency treatment of psychosis in Parkinson's disease?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Antidepressants in the treatment of psychosis with comorbid depression in Parkinson disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Ziprasidone in Parkinson's disease psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Aripiprazole and Parkinson's disease psychosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Long‐term outcome of quetiapine use for psychosis among parkinsonian patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Olanzapine treatment for dopaminergic-induced hallucinations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Successful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Dopaminergic hallucinosis with fluoxetine in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3045857

26 October 2018

Pharmacology of hallucinations induced by long-term drug therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aripiprazole associated with severe exacerbation of Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine and risperidone treatment of psychosis in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psychosis during chronic levodopa therapy triggered by the new antidepressive drug mirtazapine

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clozapine in drug-induced psychosis in Parkinson's disease. The French Clozapine Parkinson Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coping strategies for visual hallucinations in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron treatment of L-dopa-induced psychosis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Ondansetron for hallucinosis in advanced Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risperidone in Parkinson's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The malignant course of "benign hallucinations" in Parkinson disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/20842582

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11940-010-0072-Y

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

3 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34610632&oldid=1556880799"